Healthcare Review: Insmed, Dendreon, Allergan, Edwards Lifesciences, Intercept Pharmaceuticals Print E-mail
By Staff and Wire Reports   
Tuesday, 20 May 2014 12:58
U.S. stocks dipped on Tuesday, weighed down by retailers after earnings from TJX Companies and Staples. TJX shares slumped 5.7 percent to $55.07 as the biggest drag on the S&P 500 after the owner of off-price chain stores TJ Maxx and Marshalls reported lower-than-expected quarterly revenue. Staples Inc tumbled 10.8 percent to $11.95 after the office supply retailer posted first-quarter earnings and forecast a decline in sales in the current quarter. The S&P retail index fell 0.4 percent.

Shares of Insmed ($INSM +8.8%) are up in light volume in apparent response to its announcement of results from its Phase 2 clinical trial for Arikayce (liposomal amikacin for inhalation) for the treatment of treatment-resistant nontuberculous mycobacterial lung infections. Investors may not have read the entire press release, though. Although the title states "positive open label data" the product failed to achieve the primary endpoint of a statistically significant change in mycobacterial density on a seven-point scale from baseline to the end of the randomized portion of the trial. Only a positive trend was observed. It did achieve the secondary endpoint of culture conversion.

Shares of Dendreon ($DNDN +8.4%) are up in heavy volume in response to the company's presentation of data from two Provenge clinical studies at the American Urological Association meeting in Orlando. Interim data from the ProACT and IMPACT studies suggest that Provenge elicits an immune response associated with an overall survival benefit.

Allergan ($AGN) ramps up its propaganda efforts in its battle to stay out the clutches of Valeant (VRX), saying that it expects EPS to increase 20-25% in 2015 and at an annual compound rate of 20% over five years. The company also forecasts "double-digit revenue growth" next year and over the coming five years. Meanwhile, Allergan has received over 500 letters from physician customers, patient advocacy groups and medical associations expressing support for the company following its rejection of Valeant's bid.

Edwards Lifesciences ($EW) says the outcomes at 30 days in a trial of its Sapien 3 transcatheter aortic valve were "excellent." Immortality was a "very low" 2.1% and the stroke rate was 1%, while there were few access-site complications. Over 96% of patients had a mild paravalvular leak, although there were no severe such leaks.

Shares of Intercept Pharmaceuticals ($ICPT) are off 12% on mediocre volume in apparent response The Street's article stating the company's liver disease drug, obeticholic acid (OCA), may cause significant lipid abnormalities, an observation made from its Phase 3 clinical trial evaluating the drug in patients with nonalcoholic steatohepatitis (NASH). Intercept executives appear to have made the decision to downplay the potential negative ramifications of the lipid effects according to a series of January 2014 emails exchanged between the company and a division of NIH.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter